Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

A Pentavalent Epstein-Barr Virus-Like Particle Vaccine Elicits High Titers of Neutralizing Antibodies against Epstein-Barr Virus Infection in Immunized Rabbits
Gabriela M. Escalante, Joslyn Foley, Lorraine Z. Mutsvunguma, et al.
Vaccines (2020) Vol. 8, Iss. 2, pp. 169-169
Open Access | Times Cited: 27

Showing 1-25 of 27 citing articles:

Epstein–Barr virus as a leading cause of multiple sclerosis: mechanisms and implications
Kjetil Bjørnevik, Christian Münz, Jeffrey I. Cohen, et al.
Nature Reviews Neurology (2023)
Closed Access | Times Cited: 130
Burkitt lymphoma
Cristina López, Birgit Burkhardt, John K. C. Chan, et al.
Nature Reviews Disease Primers (2022) Vol. 8, Iss. 1
Closed Access | Times Cited: 80
mRNA vaccines: The future of prevention of viral infections?
Piotr Rzymski, Agnieszka Szuster−Ciesielska, Tomasz Dzieciątkowski, et al.
Journal of Medical Virology (2023) Vol. 95, Iss. 2
Closed Access | Times Cited: 49
Stress-Induced Epstein-Barr Virus Reactivation
Daniel Sausen, Maimoona Bhutta, Elisa Gallo, et al.
Biomolecules (2021) Vol. 11, Iss. 9, pp. 1380-1380
Open Access | Times Cited: 70
Virus-like Particles as Preventive and Therapeutic Cancer Vaccines
Anna Lucia Tornesello, Maria Tagliamonte, Franco M. Buonaguro, et al.
Vaccines (2022) Vol. 10, Iss. 2, pp. 227-227
Open Access | Times Cited: 67
A bivalent Epstein-Barr virus vaccine induces neutralizing antibodies that block infection and confer immunity in humanized mice
Chih‐Jen Wei, Wei Bu, Laura A. Nguyen, et al.
Science Translational Medicine (2022) Vol. 14, Iss. 643
Closed Access | Times Cited: 66
Urgency and necessity of Epstein-Barr virus prophylactic vaccines
L. Zhong, Claude Krummenacher, Wanlin Zhang, et al.
npj Vaccines (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 55
Epstein-Barr virus infection: the micro and macro worlds
Wei Huang, Lang Bai, Hong Tang
Virology Journal (2023) Vol. 20, Iss. 1
Open Access | Times Cited: 28
The Potential for EBV Vaccines to Prevent Multiple Sclerosis
P.A.C. Maple, Alberto Ascherio, Jeffrey I. Cohen, et al.
Frontiers in Neurology (2022) Vol. 13
Open Access | Times Cited: 29
A cocktail nanovaccine targeting key entry glycoproteins elicits high neutralizing antibody levels against EBV infection
L. Zhong, Wanlin Zhang, Hong Liu, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 7
CHO cells for virus-like particle and subunit vaccine manufacturing
Zalma V. Sanchez-Martinez, Sergio P. Alpuche-Lazcano, Matthew Stuible, et al.
Vaccine (2024) Vol. 42, Iss. 10, pp. 2530-2542
Open Access | Times Cited: 6
The Status and Prospects of Epstein–Barr Virus Prophylactic Vaccine Development
Cong Sun, Xinchun Chen, Yinfeng Kang, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 35
Four Decades of Prophylactic EBV Vaccine Research: A Systematic Review and Historical Perspective
Gabriela M. Escalante, Lorraine Z. Mutsvunguma, Murali Muniraju, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 21
A Chimeric Virus-Like Particle Vaccine Presenting an Immunodominant Epitope of gB Elicited Potent Neutralizing Antibodies against EBV Infection In Vitro and In Vivo
Ling Zhong, Wanlin Zhang, Rui Xiao, et al.
ACS Applied Materials & Interfaces (2025)
Closed Access
EBV Vaccines in the Prevention and Treatment of Nasopharyngeal Carcinoma
Weiwei Zhang, CHUN‐JIE WANG, Yousheng Meng, et al.
Vaccines (2025) Vol. 13, Iss. 5, pp. 478-478
Open Access
Main Targets of Interest for the Development of a Prophylactic or Therapeutic Epstein-Barr Virus Vaccine
Vincent Jean-Pierre, Julien Lupo, Marlyse Buisson, et al.
Frontiers in Microbiology (2021) Vol. 12
Open Access | Times Cited: 26
GB and gH/gL fusion machinery: a promising target for vaccines to prevent Epstein-Barr virus infection
Changqing Liu, Shan Li, Muchuan Qiao, et al.
Archives of Virology (2024) Vol. 169, Iss. 8
Closed Access | Times Cited: 3
Glycoprotein B Antibodies Completely Neutralize EBV Infection of B Cells
Junping Hong, Dongmei Wei, L. Zhong, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 15
Prophylactic and Therapeutic EBV Vaccines: Major Scientific Obstacles, Historical Progress, and Future Direction
Jing Cai, Bo‐Dou Zhang, Yuqi Li, et al.
Vaccines (2021) Vol. 9, Iss. 11, pp. 1290-1290
Open Access | Times Cited: 18
Multivalent MVA-vectored vaccine elicits EBV neutralizing antibodies in rhesus macaques that reduce EBV infection in humanized mice
Gabriela M. Escalante, Ivana Gabriela Reidel, Lorraine Z. Mutsvunguma, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 2
Assessing the Efficacy of VLP-Based Vaccine against Epstein-Barr Virus Using a Rabbit Model
Narendran Reguraman, Asma Hassani, Pretty S. Philip, et al.
Vaccines (2023) Vol. 11, Iss. 3, pp. 540-540
Open Access | Times Cited: 4
Kaposi sarcoma-associated herpesvirus complement control protein (KCP) and glycoprotein K8.1 are not required for viral infection in vitro or in vivo
Murali Muniraju, Lorraine Z. Mutsvunguma, Ivana Gabriela Reidel, et al.
Journal of Virology (2024) Vol. 98, Iss. 6
Open Access | Times Cited: 1
Rapid and Scalable Production of Functional SARS-CoV-2 Virus-like Particles (VLPs) by a Stable HEK293 Cell Pool
Sitthiphol Puarattana-aroonkorn, Kannan Tharakaraman, Disapan Suriyawipada, et al.
Vaccines (2024) Vol. 12, Iss. 6, pp. 561-561
Open Access | Times Cited: 1
An insect cell-derived extracellular vesicle-based gB vaccine elicits robust adaptive immune responses against Epstein-Barr virus
Qian Wu, Kai‐Yun Chen, Wenhui Xue, et al.
Science China Life Sciences (2024)
Closed Access | Times Cited: 1
Epstein-Barr virus: vaccine development
T. V. Solomay, Т. А. Семененко, Filatov Nn, et al.
Immunologiya (2020) Vol. 41, Iss. 4, pp. 381-390
Open Access | Times Cited: 6
Page 1 - Next Page

Scroll to top